This page is part of the FHIR Specification (v1.8.0: STU 3 Draft). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions
Provenance for Biocompute object examples (id = "obj.1001")
<Provenance xmlns="http://hl7.org/fhir"> <id value="obj.1001"/> <text><status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative with Details</b></p><p><b>id</b>: obj.1001</p><p><b>target</b>: <a>Procedure/example/_history/1.2</a></p><p><b>period</b>: 06/06/2017 --> (ongoing)</p><p><b>recorded</b>: 09/06/2016 8:12:14 AM</p><p><b>reason</b>: antiviral resistance detection (Details: [not stated] code null = 'null', stated as 'antiviral resistance detection')</p><p><b>policy</b>: <a>https://github.com/common-workflow-language/workflows/blob/master/workflows/lobSTR/lobSTR-workflow.c wl</a></p><blockquote><p><b>agent</b></p><p><b>role</b>: Author (Details: http://hl7.org/fhir/provenance-participant-role code author = 'Author', stated as 'null')</p><p><b>who</b>: <a>Practitioner/f204</a></p></blockquote><blockquote><p><b>agent</b></p><p><b>role</b>: Author (Details: http://hl7.org/fhir/provenance-participant-role code author = 'Author', stated as 'null')</p><p><b>who</b>: <a>Practitioner/f006</a></p></blockquote><blockquote><p><b>entity</b></p><p><b>role</b>: quotation</p><p><b>reference</b>: Identify baseline single nucleotide polymorphisms (SNPs[SO:0000694]), insertions[SO:0000667], and deletions[SO:0000045] that correlate with reduced ledipasvir[PubChem:67505836] antiviral drug efficacy in Hepatitis C virus subtype 1</p></blockquote><blockquote><p><b>entity</b></p><p><b>role</b>: quotation</p><p><b>reference</b>: Identify treatment emergent amino acid substitutions[SO:0000048] that correlate with antiviral drug treatment failure</p></blockquote><blockquote><p><b>entity</b></p><p><b>role</b>: quotation</p><p><b>reference</b>: Determine whether the treatment emergent amino acid substitutions[SO:0000048] identified correlate with treatment failure involving other drugs against the same virus</p></blockquote></div></text><target> <reference value="Procedure/example/_history/1.2"/> </target> <period> <start value="2017-06-06"/> </period> <recorded value="2016-06-09T08:12:14+10:00"/> <reason> <display value="antiviral resistance detection"/> </reason> <!-- reference to a patient consent to share inforamtion --> <policy value="https://github.com/common-workflow-language/workflows/blob/master/workflows/lobSTR/lobSTR-workflow.c wl"/> <!-- author = Harold Hippocrates --> <agent> <role> <system value="http://hl7.org/fhir/provenance-participant-role"/> <code value="author"/> </role> <whoReference> <reference value="Practitioner/f204"/> </whoReference> <!-- very often, the user won't have a known system - these aren't available for security system log ons. But where you can define it, you should --> </agent> <agent> <role> <system value="http://hl7.org/fhir/provenance-participant-role"/> <code value="author"/> </role> <whoReference> <reference value="Practitioner/f006"/> </whoReference> <!-- very often, the user won't have a known system - these aren't available for security system log ons. But where you can define it, you should --> </agent> <entity> <role value="quotation"/> <reference> <display value="Identify baseline single nucleotide polymorphisms (SNPs[SO:0000694]), insertions[SO:0000667], and deletions[SO:0000045] that correlate with reduced ledipasvir[PubChem:67505836] antiviral drug efficacy in Hepatitis C virus subtype 1"/> </reference> </entity> <entity> <role value="quotation"/> <reference> <display value="Identify treatment emergent amino acid substitutions[SO:0000048] that correlate with antiviral drug treatment failure"/> </reference> </entity> <entity> <role value="quotation"/> <reference> <display value="Determine whether the treatment emergent amino acid substitutions[SO:0000048] identified correlate with treatment failure involving other drugs against the same virus"/> </reference> </entity> </Provenance>
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.